However, the treatment armamentarium for IBD is expanding, with the recent approval of multiple non-TNF biologics and small molecules.34 In the near future, the combination of these novel agents may also be investigated in clinical trials or in the real-world practice. This evidence concerns the gene TNF and inflammatory bowel disease.